- Home
- SERA vs MGNX Comparison
SERA vs MGNX Comparison
Compare SERA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERA
- MGNX
- Stock Information
- Founded
- SERA 2008
- MGNX 2000
- Country
- SERA United States
- MGNX United States
- Employees
- SERA N/A
- MGNX N/A
- Industry
- SERA Precision Instruments
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- SERA Health Care
- MGNX Health Care
- Exchange
- SERA Nasdaq
- MGNX Nasdaq
- Market Cap
- SERA 208.7M
- MGNX 202.7M
- IPO Year
- SERA 2021
- MGNX 2013
- Fundamental
- Price
- SERA $4.12
- MGNX $2.76
- Analyst Decision
- SERA
- MGNX Hold
- Analyst Count
- SERA 0
- MGNX 10
- Target Price
- SERA N/A
- MGNX $7.17
- AVG Volume (30 Days)
- SERA 150.9K
- MGNX 768.5K
- Earning Date
- SERA 03-19-2025
- MGNX 03-06-2025
- Dividend Yield
- SERA N/A
- MGNX N/A
- EPS Growth
- SERA N/A
- MGNX N/A
- EPS
- SERA N/A
- MGNX N/A
- Revenue
- SERA $94,000.00
- MGNX $141,329,000.00
- Revenue This Year
- SERA N/A
- MGNX $174.73
- Revenue Next Year
- SERA $3,081.82
- MGNX N/A
- P/E Ratio
- SERA N/A
- MGNX N/A
- Revenue Growth
- SERA N/A
- MGNX 16.68
- 52 Week Low
- SERA $3.84
- MGNX $2.34
- 52 Week High
- SERA $12.36
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- SERA 31.08
- MGNX 45.32
- Support Level
- SERA $3.89
- MGNX $2.34
- Resistance Level
- SERA $4.46
- MGNX $2.95
- Average True Range (ATR)
- SERA 0.43
- MGNX 0.17
- MACD
- SERA -0.00
- MGNX 0.03
- Stochastic Oscillator
- SERA 10.22
- MGNX 61.76
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).